Alkermes plc $ALKS Shares Sold by Primecap Management Co. CA

Primecap Management Co. CA cut its holdings in Alkermes plc (NASDAQ:ALKS) by 4.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,759,080 shares of the company’s stock after selling 143,430 shares during the period. Primecap Management Co. CA owned about 1.67% of Alkermes worth $82,772,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Assetmark Inc. increased its holdings in shares of Alkermes by 933.8% in the 3rd quarter. Assetmark Inc. now owns 827 shares of the company’s stock valued at $25,000 after acquiring an additional 747 shares during the last quarter. Hantz Financial Services Inc. boosted its holdings in Alkermes by 395.6% in the third quarter. Hantz Financial Services Inc. now owns 1,239 shares of the company’s stock valued at $37,000 after purchasing an additional 989 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. acquired a new position in Alkermes in the second quarter valued at approximately $49,000. Osaic Holdings Inc. increased its stake in Alkermes by 56.4% in the second quarter. Osaic Holdings Inc. now owns 1,945 shares of the company’s stock valued at $56,000 after purchasing an additional 701 shares during the last quarter. Finally, Bessemer Group Inc. raised its holdings in Alkermes by 163.3% during the third quarter. Bessemer Group Inc. now owns 2,222 shares of the company’s stock worth $67,000 after purchasing an additional 1,378 shares in the last quarter. 95.21% of the stock is owned by hedge funds and other institutional investors.

Alkermes Stock Down 1.0%

Shares of ALKS stock opened at $30.73 on Friday. The stock’s 50-day moving average price is $31.50 and its 200 day moving average price is $30.18. The stock has a market capitalization of $5.07 billion, a PE ratio of 21.49 and a beta of 0.49. Alkermes plc has a 52-week low of $25.17 and a 52-week high of $36.32.

Alkermes (NASDAQ:ALKS) last posted its quarterly earnings data on Wednesday, February 25th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.14). Alkermes had a return on equity of 14.91% and a net margin of 16.37%.The company had revenue of $384.55 million for the quarter, compared to analyst estimates of $380.44 million. During the same period in the previous year, the business posted $1.05 earnings per share. The firm’s revenue was down 10.6% compared to the same quarter last year. Alkermes has set its FY 2026 guidance at -0.798–0.680 EPS. Analysts expect that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALKS has been the subject of several research analyst reports. Weiss Ratings restated a “hold (c+)” rating on shares of Alkermes in a report on Monday, December 29th. Bank of America boosted their price target on shares of Alkermes from $33.00 to $34.00 and gave the company a “neutral” rating in a research report on Friday, February 20th. HC Wainwright reaffirmed a “neutral” rating and set a $43.00 price objective on shares of Alkermes in a report on Thursday. Royal Bank Of Canada cut their target price on Alkermes from $47.00 to $45.00 and set an “outperform” rating on the stock in a research report on Thursday. Finally, Truist Financial boosted their target price on Alkermes from $50.00 to $55.00 and gave the company a “buy” rating in a report on Monday, November 17th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Alkermes has an average rating of “Moderate Buy” and a consensus target price of $44.07.

Insider Activity at Alkermes

In other Alkermes news, EVP Craig C. Hopkinson sold 9,000 shares of the company’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $33.93, for a total transaction of $305,370.00. Following the completion of the transaction, the executive vice president owned 57,740 shares in the company, valued at approximately $1,959,118.20. This represents a 13.49% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Shane Cooke sold 61,200 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $34.57, for a total transaction of $2,115,684.00. Following the completion of the sale, the director owned 103,744 shares of the company’s stock, valued at $3,586,430.08. This trade represents a 37.10% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 148,148 shares of company stock valued at $5,028,378 in the last 90 days. Company insiders own 4.40% of the company’s stock.

Alkermes News Summary

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Brokerage bullishness — Wolfe Research initiated coverage with an “outperform” and a $45 price target, and Wells Fargo raised its target to $43 with an “overweight” rating; both signal analyst conviction on upside potential. Wolfe Research initiation Wells Fargo target raise
• Neutral Sentiment: Top-line mostly in line — Q4 revenue (~$384.6M) was roughly in-line/just above consensus, which reduces immediate fundamental concern on sales. Company press release / slide deck
• Neutral Sentiment: Analyst divergence — RBC nudged its price target down (from $47 to $45) but maintained an “outperform” view, reflecting continued upside in estimates despite some analyst calibration. RBC note
• Neutral Sentiment: Short-interest data appears unreliable — recent feeds show zero shares reported and a 0.0 days ratio, suggesting reporting errors rather than a real short-squeeze signal. (Watch for cleaned data in coming days.)
• Negative Sentiment: Profitability miss and weak EPS outlook — Alkermes reported EPS below consensus (company-stated ~$0.29 vs. ~$0.43 expected) and issued FY2026 EPS guidance of roughly -0.80 to -0.68, a sharp downgrade versus street expectations; that swing in earnings outlook is the primary negative driver. Q4 results & guidance
• Negative Sentiment: CEO succession / leadership change created near-term uncertainty — the company announced Richard Pops will retire as CEO on July 31, 2026 with Blair Jackson named successor; the market reacted negatively to the combination of leadership transition and the earnings/guidance news. CEO succession press release Market reaction coverage

Alkermes Company Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.